Drug Overview
Darzalex (daratumumab; Johnson & Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in other tissues.
By binding to this protein, Darzalex induces myeloma cell death by several different mechanisms including apoptosis and antibody- and complement-dependent cytotoxicity.
Darzalex (daratumumab; Johnson & Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in other tissues.
By binding to this protein, Darzalex induces myeloma cell death by several different mechanisms including apoptosis and antibody- and complement-dependent cytotoxicity.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Darzalex : Multiple myeloma
Darzalex : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
Figure 1: Darzalex for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Darzalex for multiple myeloma
Figure 3: The authors drug assessment summary of Darzalex for multiple myeloma
Figure 4: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Darzalex for mantle cell lymphoma – SWOT analysis
LIST OF TABLES
Table 1: Darzalex drug profile
Table 2: Darzalex pivotal trial data in multiple myeloma
Table 3: Darzalex early-phase trial data in multiple myeloma
Table 4: Darzalex Phase III trials in multiple myeloma
Table 5: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 7: Darzalex drug profile
Table 8: Darzalex Phase II trial in mantle cell lymphoma
